论文部分内容阅读
目的：观察参麦注射液对恶性肿瘤化疗时增效减毒作用的疗效和安全性。方法：１２２ 例经病理确诊、给予化学抗癌药物治疗的恶性肿瘤患者随机分为２ 组。治疗组在化疗开始之日起加用参麦注射液４０ ｍ ｌ＋ １０％葡萄糖２５０ ｍ ｌ中静滴，每日１ 次，１４ 日为１ 个疗程；对照组单纯化疗，未加用参麦注射液。２ 组患者化疗方案基本相似。观察２ 组疗效。结果：对恶性肿瘤的疗效，治疗组完全缓解６ 例（８．５％ ），部分缓解３８ 例（５３．５％ ），稳定２０ 例（２８．２％ ），病变进展７ 例（９．９％ ）；对照组完全缓解１ 例（２．０％ ），部分缓解１６ 例（３１．４％ ），稳定２３ 例（４５．１％ ），病变进展１１ 例（２１．６％ ），２ 组经Ｒｉｄｉｔ分析，ｕ＝ ３．００７ ２，Ｐ＜ ０．０１。治疗组治疗恶性肿瘤疗效显著优于单纯对照组；２ 组止恶心及预防呕吐作用亦有非常显著性差异（Ｐ均＜ ０．０１）。结论：参麦注射液是一种安全、有效的恶性肿瘤化疗时增效减毒药，值得临床推广应用。
OBJECTIVE: To observe the efficacy and safety of Shenmai injection in enhancing the efficacy of attenuated chemotherapy in malignant tumors. Methods: A total of 122 patients with malignant tumors diagnosed by pathology and treated with chemical anticancer drugs were randomly divided into 2 groups. The treatment group was treated with Shenmai injection (40 ml + 10% glucose 250 ml) from the start of chemotherapy on a daily basis, once a day, and 14 days as a course of treatment; the control group was treated with chemotherapy alone without Shenmai Injection. liquid. The chemotherapy regimens in the two groups were basically similar. Observed the efficacy of the 2 groups. Results: For the treatment of malignant tumors, 6 cases (8.5%) were completely relieved in the treatment group, 38 cases (53.5%) partially relieved, 20 cases (28.2%) stable, and 7 cases progressed (9.9 cases). %); The control group achieved complete remission in one case (2.0%), partial remission in 16 cases (31.4%), stability in 23 cases (45.1%), progression of disease in 11 cases (21.6%), and 2 groups. Analysis by Ridit, u = 3.007 2, P < 0.01. The therapeutic effect of the treatment group was significantly better than that of the control group; the effect of the two groups on nausea and vomiting was also significantly different (P < 0.01). Conclusion: Shenmai injection is a safe, effective and effective antiviral drug for malignant tumors. It is worthy of clinical application.